CDMOs can claim credit for the robust growth of emerging bio/pharma financings.
The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.
Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.
Mergers and acquisitions are positive for the CDMO industry, but there is a downside.